The DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents
Buckner, J.C.; Moynihan, T.J.
New England Journal of Medicine 344(9): 686; Author Reply 687-688
2001
ISSN/ISBN: 0028-4793 PMID: 11229337 Document Number: 531687
Document emailed within 1 workday
Related Documents
Lomova, T.I.; Shakhova, I.K.; Shkodinskaia, E.N. 1981: Repair of DNA-protein cross-links induced by antineoplastic alkylating agents Biulleten' Eksperimental'noi Biologii i Meditsiny 92(7): 74-76Papadopoulou, M.V.; Bloomer, W.D. 2007: DNA repair mechanisms are involved in the hypoxia-dependent toxicity of NLCQ-1 (NSC 709257) and its synergistic interaction with alkylating agents In Vivo 21(2): 175-180
Kramář, F.; Minárik, M.; Benešová, L.; Halková, T.; Netuka, D.; Bradáč, O.; Beneš, V. 2016: IDH1/2 Mutation and MGMT Promoter Methylation - the Relevant Survival Predictors in Czech Patients with Brain Gliomas Folia Biologica 62(5): 194-202
Luo, M.; Kelley, M.R. 2004: Inhibition of the human apurinic/apyrimidinic endonuclease (APE1) repair activity and sensitization of breast cancer cells to DNA alkylating agents with lucanthone Anticancer Research 24(4): 2127-2134
Catane, R. 1978: Clinical experience with estramustine phosphate and predinimustine, two steroidal alkylating agents compounds Cancer Treatment Reports 62(8): 1264-1265
Spears, C.P. 1981: Nucleophilic selectivity ratios of model and clinical alkylating agents by 4-(4'-nitrobenzyl)pyridine competition Molecular Pharmacology 19(3): 496-504
Spiro, T.; Liu, L.; Gerson, S. 2000: New cytotoxic agents for the treatment of metastatic malignant melanoma: temozolomide and related alkylating agents in combination with guanine analogues to abrogate drug resistance Forum 10(3): 274-285
MacInnes, M.A.; Mudgett, J.S. 1990: Cloning of the functional human excision repair gene ERCC-5: potential gene regulatory features conserved with other human repair genes Progress in Clinical and Biological Research 340a: 265-274
Lind, M.J.; Ardiet, C. 1993: Pharmacokinetics of alkylating agents Cancer Surveys 17: 157-188
Bignold, L.P. 2006: Alkylating agents and DNA polymerases Anticancer Research 26(2b): 1327-1336
Frei, E. 1991: The modulation of alkylating agents Seminars in Hematology 28(3 Suppl 4: 22-24
Schmidt, C.G. 1971: Alkylating cytostatic agents Der Internist 12(Suppl 1): 119-127
Preusser, M.; Berghoff, A.S.; Manzl, C.; Filipits, M.; Weinhäusel, A.; Pulverer, W.; Dieckmann, K.; Widhalm, G.; Wöhrer, A.; Knosp, E.; Marosi, C.; Hainfellner, J.A. 2014: Clinical Neuropathology practice news 1-2014: pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastoma Clinical neuropathology 33(1): 6-14
Iamshanov, V.A.; Kraĭz, B.O.; Petrov, A.S. 1973: Interaction of DNA with alkylating agents of different classes Voprosy Onkologii 19(2): 60-62
Schmähl, D. 1986: Carcinogenicity of anticancer drugs and especially alkylating agents Iarc Scientific Publications 78: 29-35
Lisker, S.A. 1970: Chemotherapy for malignant disease: the alkylating agents Delaware Medical Journal 42(5): 127-130
Babaian, I.S.; Khudaverdian, N.V.; Karapetian, L.G.; Kazarian, R.S.; Sogomonian, L.R. 1997: Comparative study of three antineoplastic alkylating agents on DNA Biofizika 42(2): 542-543
Canellos, G.P. 1989: The role of alkylating agents in acute and chronic leukemia Bone Marrow Transplantation 4(Suppl 1): 46-47
Mittelman, A.; Catane, R.; Murphy, G.P. 1977: New steroidal alkylating agents in advanced stage D carcinoma of the prostate Cancer Treatment Reports 61(2): 307-310
Romanova, I.N. 1972: Effect of alkylating agents on the ATPase activity of liver mitochondria Biokhimiia 37(4): 846-850